BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.